Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CSAG2 Blocking Peptide (N-term)
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9Y5P2 |
|---|---|
| Other Accession | NP_001074317.2, NP_001123300.1, NP_001123298.1, NP_004900.2 |
| Gene ID | 389903 |
|---|---|
| Other Names | Chondrosarcoma-associated gene 2/3 protein, Cancer/testis antigen 242, CT242, Taxol-resistant-associated gene 3 protein, TRAG-3, CSAG2, TRAG3 |
| Target/Specificity | The synthetic peptide sequence is selected from aa 14-27 of HUMAN CSAG2 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | CSAG2 |
|---|---|
| Synonyms | TRAG3 |
| Function | Drug-resistance related protein, its expression is associated with the chemotherapy resistant and neoplastic phenotype. May also be linked to the malignant phenotype. |
| Tissue Location | Weakly expressed in kidney. Expressed in various tumor cell lines including carcinomas, myeloid and lymphoid malignancies, melanomas and prostate cancer. Overexpressed in taxol- resistant breast cancer line MDA 435TR and the doxorubicin-resistant multiple myelanoma lines RPMI-8226/Dox40 and RPMI-8226/MDR10V |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
Hansen, M.A., et al. Mol. Reprod. Dev. 75(2):219-229(2008)
Janjic, B., et al. J. Immunol. 177(4):2717-2727(2006)
Ohta, M., et al. Oncol. Rep. 15(6):1529-1532(2006)
Yao, X., et al. Cancer Genet. Cytogenet. 151(1):1-13(2004)
Lin, C., et al. Gene 285 (1-2), 269-278 (2002) :
Venter, J.C., et al. Science 291(5507):1304-1351(2001)
Feller, A.J., et al. Anticancer Res. 20 (6B), 4147-4151 (2000) :
Duan, Z., et al. Gene 229 (1-2), 75-81 (1999) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
